Imatinib (Gleevec®, Glivec®) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry

被引：11

作者：

Guetens, G

Prenen, H

De Boeck, G

Highley, M

de Wever, I

van Oosterom, AT

de Bruijn, EA

机构：

[1] Derriford Hosp, Plymouth Oncol Ctr, Plymouth PL6 8DH, Devon, England

[2] Katholieke Univ Leuven, UZ Gasthuisberg, Dept Surg Oncol, Louvain, Belgium

[3] Univ Antwerp, Dept Med Oncol, Lab Canc Res & Clin Oncol, B-2020 Antwerp, Belgium

[4] Univ Antwerp, Dept Chem, B-2020 Antwerp, Belgium

[5] Leuven Canc Inst, Louvain, Belgium

来源：

JOURNAL OF SEPARATION SCIENCE | 2006年 / 29卷 / 03期

关键词：

imatinib; liquid chromatography; mass spectrometry; sediment; tumour tissue analysis;

D O I：

10.1002/jssc.200500349

中图分类号：

O65 [分析化学];

学科分类号：

070302 [分析化学]; 081704 [应用化学];

摘要：

The analysis of the signal transduction inhibitor imatinib in patient tumour tissue using LC and MS/MS is described. The anticancer agent is eluted over RP-C18 within 2 min together with its internal standard ST1571-d8. Calibration curves were prepared in red blood cells (RBC). For quantitative isolation of the RBC, measurement of sediment was applied. There were no indications of signal suppression by substances originating in the biological matrix. The limit of determination in turnout tissue was in the range of those recorded for RBC and plasma. The assay is selective and sensitive, with its robustness favouring the experimental application in clinical oncology and its routine use in animal experiments. The LOD was 4.5 ng per gram in tumour tissue.

引用

页码：453 / 459

页数：7

共 10 条

[1]

High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].

Bakhtiar, R ;

Lohne, J ;

Ramos, L ;

Khemani, L ;

Hayes, M ;

Tse, F .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340

[2]

Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry [J].

Bakhtiar, R ;

Khemani, L ;

Hayes, M ;

Bedman, T ;

Tse, F .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1183-1194

[3]

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment [J].

Dumez, H ;

Guetens, G ;

De Boeck, G ;

Highley, MS ;

Maes, RAA ;

van Oosterom, AT ;

de Bruijn, EA .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (11) :1219-1227

[4]

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry [J].

Guetens, G ;

De Boeck, G ;

Highley, M ;

Dumez, H ;

Van Oosterom, AT ;

de Bruijn, EA .

JOURNAL OF CHROMATOGRAPHY A, 2003, 1020 (01) :27-34

[5]

Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy [J].

Maki R.G. .

Current Treatment Options in Gastroenterology, 2004, 7 (1) :13-17

[6]

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations [J].

Schleyer, E ;

Pursche, S ;

Köhne, CH ;

Schuler, U ;

Renner, U ;

Gschaidmeier, H ;

Freiberg-Richter, J ;

Leopold, T ;

Jenke, A ;

Bonin, M ;

Bergemann, T ;

le Coutre, P ;

Gruner, M ;

Bornhäuser, M ;

Ottmann, OG ;

Ehninger, G .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 799 (01) :23-36

[7]

TOSONI A, 2004, ANTICANCER THER, V4, P595

[8]

Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples [J].

Velpandian, T ;

Mathur, R ;

Agarwal, NK ;

Arora, B ;

Kumar, L ;

Gupta, SK .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 804 (02) :431-434

[9]

Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection [J].

Widmer, N ;

Béguin, A ;

Rochat, B ;

Buclin, T ;

Kovacsovics, T ;

Duchosal, MA ;

Leyvraz, S ;

Rosselet, A ;

Biollaz, J ;

Decosterd, LA .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 803 (02) :285-292

[10]

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg [J].

Zalcberg, JR ;

Verweij, J ;

Casali, PG ;

Le Cesne, A ;

Reichardt, P ;

Blay, JY ;

Schlemmer, M ;

Van Glabbeke, M ;

Brown, M ;

Judson, IR .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) :1751-1757

← 1 →